Project Grant K23AI177689
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $189,146 Project Grant to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a five-year research career development initiative spanning August 5, 2025, through July 31, 2030. The award supports a structured research program investigating the mechanisms of Pseudomonas aeruginosa adaptation, colonization, and host responses in pediatric...
- This $294,244 Project Grant award, funded by the Department of Health and Human Services (DHHS) Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, supports research to identify sepsis phenotypes associated with antibiotic-resistant pathogens. The project aims to leverage machine learning techniques, including large language models applied to clinical notes, to augment electronic health record (EHR) data and define...
- This National Institutes of Health National Heart Lung and Blood Institute project grant of $460,175.84 supports research into the effects of acidosis on pneumonia through December 31, 2021. The award funds a study at the University of South Alabama examining how the carbonic anhydrase IX isoform and cytotoxic amyloid proteins impact pulmonary endothelial cell function during Pseudomonas aeruginosa infection. Specifically, the research will test the hypotheses that CA IX is critical to acid...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $178,846 Project Grant to the University of California, San Diego, effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative investigates optimal ventilator management strategies for patients with Acute Respiratory Distress Syndrome (ARDS) on veno-venous extracorporeal membrane oxygenation (V-V ECMO). The project will...
- Grant Award Summary The University of Texas MD Anderson Cancer Center received a $152,097 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025 through August 31, 2030. This award supports comprehensive preclinical research investigating the pathogenesis of secondary mold pneumonias that occur following influenza and respiratory syncytial virus (RSV) infections,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $192,672 to The Leland Stanford Junior University under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research initiative beginning September 1, 2025 and concluding August 31, 2030. The research project investigates the role of Pseudomonas fluorescens (PF) bacteriophage in promoting Pseudomonas aeruginosa (PA) chronic lung...
- Federal Project Grant Award Summary Albany Medical College received a $451,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 6, 2026, with completion targeted for January 31, 2028. The research project investigates the role of the Wnt/β-catenin signaling pathway in alveolar epithelial repair during tuberculosis (TB) infection and examines how chronic Type I interferon...
- This $498,000 project grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) on August 16, 2025, supports research conducted by Dr. Zhengjie Zhou at Temple University in Philadelphia, PA through July 31, 2028. The award funds the research and development phase (R00 portion) of an NIH Mentored Career Award (K99/R00) focused on formulating novel lung-targeting lipid nanoparticles (LNPs) for cell-specific messenger...
- Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $185,578 Project Grant on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the Mode of Ventilation During Critical Illness at Multiple Centers (MODEM) Trial through July 31, 2030. Principal Investigator Dr. Kevin P. Seitz, an instructor in the Division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt, will...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $319,248 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2030. The award funds research into hypoxia-inducible factor (HIF)-driven modulation of alveolar regeneration, with the goal of developing transformative disease-modifying treatments for idiopathic pulmonary fibrosis (IPF) and...
PERSONALIZING ANTIMICROBIAL USE IN VENTILATOR-ASSOCIATED PNEUMONIA - CANDIDATE'S LONG-TERM CAREER GOALS: TO BECOME AN INDEPENDENT CLINICAL INVESTIGATOR THAT STRENGTHENS ICU ANTIMICROBIAL STEWARDSHIP AND PERSONALIZES ANTIBIOTIC USE IN NOSOCOMIAL PNEUMONIA. CLINICAL PROBLEMS TO BE ADDRESSED WITH THIS PROJECT: VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IS COMMON, COSTLY, AND A LEADING CAUSE OF MORBIDITY AND MORTALITY IN HOSPITALIZED PATIENTS. THE PRESENT STANDARD OF CARE IN VAP IS TREAT ALL CASES WITH 7 DAYS OF ANTIBIOTICS, REGARDLESS OF PATIENT OR PATHOGEN. THIS INFLEXIBLE APPROACH GENERATES BOTH ANTIBIOTIC OVERTREATMENT AND UNDERTREATMENT OF THE DIVERSE GROUP OF PATIENTS AFFECTED BY VAP. SPECIFIC AIMS: A LACK OF RELIABLE BIOMARKERS TO ASCERTAIN CURE OF INFECTION AND USE OF ANTIQUATED DICHOTOMOUS TRIAL OUTCOMES THAT DO NOT REFLECT BEDSIDE CLINICAL PRIORITIES HAVE IMPEDED OUR ABILITY TO PERSONALIZE VAP ANTIBIOTIC TREATMENT DURATIONS (ATDS). DR. ALBIN AIMS TO 1) IDENTIFY UNIQUE VAP-SPECIFIC ALVEOLAR BIOMARKERS TO GUIDE ATDS, AND 2) VALIDATE PRAGMATIC, HIERARCHICAL ANALYTIC METHODOLOGIES FOR FUTURE VAP ATD TRIALS. CANDIDATE'S BACKGROUND: DR. ALBIN IS ASSISTANT PROFESSOR IN INFECTIOUS DISEASES AT THE UNIVERSITY OF MICHIGAN (UM). HE HAS 20 PUBLICATIONS, INCLUDING 12 ORIGINAL RESEARCH MANUSCRIPTS AND 11 FIRST-AUTHOR PEER-REVIEWED PUBLICATIONS. DR. ALBIN HAS CORE TRAINING IN INTRODUCTORY BIOSTATISTICS AND EPIDEMIOLOGY AND IS A GRADUATE OF THE UM CLINICAL TRIALS ACADEMY. HIS WORK HAS BEEN SUPPORTED BY A MICHIGAN INSTITUTE FOR CLINICAL & HEALTH RESEARCH CATALYST AWARD AND INTERNAL FUNDING FROM THE UM DEPARTMENT OF INTERNAL MEDICINE. CAREER DEVELOPMENT PLAN: TO MEET HIS GOALS, DR. ALBIN SEEKS ADVANCED METHODOLOGIC TRAINING IN APPLIED DATA SCIENCE, CLINICAL EPIDEMIOLOGY, TRIAL DESIGN/ANALYSIS AND REVEALED PREFERENCE SURVEY METHODS, AS WELL AS EXPERIENTIAL TRAINING IN ALVEOLAR BIOSPECIMEN COLLECTION/ICU TRIAL PERFORMANCE. HIS 5-YEAR PLAN INCLUDES DIDACTIC COURSES THAT BUILD ON HIS CORE TRAINING, PROJECT-BASED MENTORING BY EXPERTS, CAREER ADVANCEMENT ACTIVITIES, AND SPECIFIC MILESTONES TO ENSURE A SUCCESSFUL TRANSITION TO INDEPENDENCE. DR. ALBIN'S PRIMARY MENTOR IS KEITH KAYE, MD, MPH. HIS CO-MENTORS ARE ROBERT DICKSON, MD; KRISHNA RAO, MD, MS; AND RICHARD WUNDERINK, MD. DELIVERABLES: THIS PROJECT WILL IDENTIFY CLINICALLY TRANSLATABLE VAP-SPECIFIC ALVEOLAR BIOMARKERS AND PRAGMATIC, HIERARCHICAL VAP TRIAL ANALYTIC METHODOLOGIES. COUPLED WITH THE DIDACTIC AND EXPERIENTIAL TRAINING ENCOMPASSED IN THE CAREER DEVELOPMENT PLAN, THIS AWARD WILL COMPETITIVELY POSITION DR. ALBIN FOR R-SERIES WORK AIMED AT STRENGTHENING ICU ANTIMICROBIAL STEWARDSHIP AND PERSONALIZING ANTIBIOTIC USE IN PNEUMONIA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $194.4k | 5/23/25 | ||
| Not listed | $194.4k | 6/17/24 | ||
| Not listed | $194.4k | 6/17/24 |